Kazia Therapeutics (KZIA) EBITDA Margin (2016)

Kazia Therapeutics' (KZIA) quarterly EBITDA Margin came in at 2965.06% in Q4 2016.

Kazia Therapeutics (KZIA) EBITDA Margin (2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 1 years of EBITDA Margin data on file, last reported at 2965.06% in Q4 2016.

Quarterly EBITDA Margin changed N/A year-over-year to 2965.06% in Q4 2016, while the trailing twelve-month figure through Dec 2016 was 138.05% (changed N/A YoY) and the FY2025 annual result came in at 53447.62%, down 5227565.0% from the prior year.
EBITDA Margin held at 2965.06% in Q4 2016.
In the past five years, EBITDA Margin ranged from a high of 2965.06% in Q4 2016 to a low of 2965.06% in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	-2,965.06%